Moderna agreed to settle litigation with Arbutus Biopharma and Genevant/Roivant, paying $950 million up front and accepting potential additional payments that could bring the total to $2.25 billion, while obtaining a global non‑exclusive license for certain lipid nanoparticle (LNP) applications. The deal resolves multi‑jurisdictional disputes over the LNP delivery technology used in Spikevax and related vaccines, removes a major legal overhang and preserves Moderna’s ability to use LNPs for infectious-disease vaccines. Moderna will record the immediate charge and pursue a narrow legal appeal on a related government‑contract immunity issue tied to contingent payments, per company statements and court filings.